Effect of mifepristone on endometrial matrix metalloproteinase expression and leukocyte abundance in new medroxyprogesterone acetate users

Li, Aimin; Felix, Juan C.; Yang, Wein-Duo; Xiong, David W.; Minoo, Parviz; Jain, John K.

doi:10.1016/j.contraception.2007.03.005

Cited by 15 publications

(7 citation statements)

References 72 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is known that endometrial proliferation depends on oestrogen level, which causes the progressive growth of functional endometrium in the proliferative phase 29 . Flavonoids and triterpenes are components of green tea that move like oestrogen,30, 31, 32, 33 but this study showed no significant result.…”

Section: Discussioncontrasting

confidence: 55%

Protective effect of green tea on tunica adventitia and endothelial changes resulting from depot medroxy progesterone acetate

Veri

Mutiah

et al. 2019

Journal of Taibah University Medical Sciences

View full text Add to dashboard Cite

Objective This study aimed to analyse the effects of green tea in inhibiting uterine atrophy and vascular changes due to the use of depot medroxy progesterone acetate (DMPA). Methods Twenty-five female Wistar rats aged one to two months were randomly assigned to five treatment groups: control group, DMPA-induced group, and DMPA-induced group orally treated with green tea extract (at 10.8 mg/day, 21.6 mg/day, or 43.2 mg/day). Histologic analysis of uterine and vascular tissues was performed with haematoxylin-eosin staining. Results DMPA decreased the thickness of endometrium and tunica adventitia, as well as significantly decreased endothelial cell count ( p < 0.05). DMPA-induced decreases in the thickness of tunica adventitia and endothelial cell count could be significantly inhibited by green tea extract ( p < 0.05). Conclusion This study concluded that DMPA triggered the depletion of uterine endometrium and vascular tunica adventitia and decreased endothelial cell count. Green tea extract at the highest dose normalized tunica adventitia and endothelial changes to the basal value.

show abstract

Section: Discussioncontrasting

confidence: 55%

Protective effect of green tea on tunica adventitia and endothelial changes resulting from depot medroxy progesterone acetate

Veri

Mutiah

et al. 2019

Journal of Taibah University Medical Sciences

View full text Add to dashboard Cite

show abstract

“…Results from those studies 110 confirmed good maximum serum LNG levels at 6 and 12 hours following administration. In addition, 114 when women with ovarian follicles of 12–14 mm, 15–17 mm, or ≥18 mm in diameter used either CARRA/LNG or CARRA gel alone, no follicular rupture occurred in the 5-day period following administration in 74% of the CARRA/LNG treatment cycles and in 30% of the CARRA gel cycles. Sexual intercourse did not interfere with the absorption rate of the gel.…”

Section: New Contraceptive Methods Recently Launched In Different Marmentioning

confidence: 92%

New and emerging contraceptives: a state-of-the-art review

Bahamondes¹,

Bahamondes²

2014

IJWH

View full text Add to dashboard Cite

BackgroundThe first hormonal contraceptive was introduced onto the market in several countries 50 years ago; however, the portfolio of contraceptive methods remains restricted with regards to their steroid composition, their cost, and their ability to satisfy the requirements of millions of women/couples in accordance with their different reproductive intentions, behaviors, cultures, and settings.MethodsA literature review was conducted using Medline, Embase, and Current Contents databases, up to September 1, 2013 to identify publications reporting new contraceptives in development using combinations of the search terms: contraception, contraceptives, oral contraceptives, patch, vaginal ring, implants, intrauterine contraceptives, and emergency contraception (EC). Also, several experts in the field were also consulted to document ongoing projects on contraception development. Additionally, the Clinicaltrial.gov website was searched for ongoing studies on existing contraceptive methods and new and emerging female contraceptives developed over the past 5 years. Information was also obtained from the pharmaceutical industry.ResultsEarly sexual debut and late menopause means that women may require contraception for up to 30 years. Although oral, injectable, vaginal, transdermal, subdermal, and intrauterine contraceptives are already available, new contraceptives have been developed in an attempt to reduce side effects and avoid early discontinuation, and to fulfill women’s different requirements. Research efforts are focused on replacing ethinyl-estradiol with natural estradiol to reduce thrombotic events. In addition, new, less androgenic progestins are being introduced and selective progesterone receptor modulators and new delivery systems are being used. In addition, research is being conducted into methods that offer dual protection (contraception and protection against human immunodeficiency virus transmission), and contraceptives for use “on demand.” Studies are also investigating non-hormonal contraceptive methods that have additional, non-contraceptive benefits.ConclusionThe most pressing need worldwide is, first, that the highly effective contraceptive methods already available should be affordable to most of the population and also that these methods should fulfill the needs of women of different ages and with different reproductive requirements. The development of new contraceptive methods should also take advantage of the knowledge obtained over the past 30 years on gamete physiology and gamete interaction to avoid the use of steroid compounds.

show abstract

“…Treatment of mifepristone significantly downregulated the expression of neuronal nitric oxide synthase (nNOS) and N-methyl-D-aspartate receptor subunit 2B (NR2B) proteins in a rat model of radicular pain [19]. Furthermore, Li et al reported that addition of mifepristone to depot-medroxyprogesterone acetate (DMPA)-exposed endometrium significantly decreased mast tryptase-positive cells and pointed that mifepristone is associated with inhibiting the activity of mast cells [20]. Some studies in China and we also found that mifepristone could be applied in the treatment of adenomyosis.…”

Section: Ivyspringmentioning

confidence: 99%

The new application of mifepristone in the relief of adenomyosis-caused dysmenorrhea

Che

Wang

et al. 2020

Int. J. Med. Sci.

View full text Add to dashboard Cite

Background: Adenomyosis is a quite common gynecological disorder and above 30% of patients have typical secondary and progressive dysmenorrhea. Current treatments still have many disadvantages and thereby the novel treatment aiming to relieve dysmenorrhea still needs to be further investigated. Mifepristone is a wonderful drug because it is effective, safe and cheap in many diseases including adenomyosis. In this study, we aim to investigate if mifepristone could be used in the treatment of adenomyosis-associated dysmenorrhea. Methods: Human primary endometrial epithelial and stromal cells from adenomyosis patients were isolated and treated with mifepristone. RNA-sequencing was then performed to detect the gene changes of pain-related inflammatory mediators. Meanwhile, the effect of mifepristone on the infiltration and degranulation of mast cells were investigated in adenomyosis lesions. Additionally, the role of mifepristone on the density of nerve fibers was also studied in the ectopic endometrium. At last, to evaluate the therapeutic efficacy of mifepristone on dysmenorrhea of adenomyosis, twenty participants were included and the visual analog scale (VAS) score was assessed and compared before and after treatment with mifepristone. Results: We demonstrated that mifepristone reduced the secretion of IL-6 and TNF-α from endometrial epithelial and stromal cells, restricted the infiltration and degranulation of mast cells in eutopic and ectopic endometrium and decreased the density of nerve fibers by inhibiting the migration capacity of nerve cells in adenomyosis. Meanwhile, we found that mifepristone could significantly relieve dysmenorrhea of adenomyosis. Conclusion: The findings demonstrated that mifepristone could be applied in the treatment of dysmenorrhea for the adenomyosis patients.

show abstract

Effect of mifepristone on endometrial matrix metalloproteinase expression and leukocyte abundance in new medroxyprogesterone acetate users

Cited by 15 publications

References 72 publications

Protective effect of green tea on tunica adventitia and endothelial changes resulting from depot medroxy progesterone acetate

Protective effect of green tea on tunica adventitia and endothelial changes resulting from depot medroxy progesterone acetate

New and emerging contraceptives: a state-of-the-art review

The new application of mifepristone in the relief of adenomyosis-caused dysmenorrhea

Contact Info

Product

Resources

About